Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01458340 · ClinicalTrials.gov registry record · Phase 2

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 study of ADHD and Attention Deficit/Hyperactivity Disorder, sponsored by Theravance Biopharma.

Completed
Registry status
Phase 2
Development phase
295
Enrollment target
17
Study locations

NCT01458340 is a Phase 2 study of ADHD and Attention Deficit/Hyperactivity Disorder that has completed, run by Theravance Biopharma. The registered enrollment target is 295 participants, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (59% higher). The trial reports 17 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01458340, a Phase 2 study of ADHD and Attention Deficit/Hyperactivity Disorder, has completed, sponsored by Theravance Biopharma.

COMPLETED
Registry status
Phase 2
Development phase
295 participants
Enrollment target
17
Study locations

Study Summary

The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.

Interventions

  • DRUG Placebo
  • DRUG TD-9855

Study Locations (17)

Florida

  • Florida Clinical Research Center, LLC - Bradenton
  • Clinical Neuroscience Solutions, Inc. - Jacksonville
  • Florida Clinical Research Center - Maitland
  • Janus Ctr. for Psychiatric Research - Palm Beach

Utah

  • Psychiatric & Behavioral Solutions - Salt Lake City
  • Lifetree Clinical Research, LC - Salt Lake City

Georgia

  • Carman Research - Smyrna

Kansas

  • Psychiatric Associates - Overland Park

Missouri

  • Midwest Research Group - Saint Charles

Nevada

  • Ctr. for Psychiatry & Behavioral Med. - Las Vegas

New York

  • Adult ADHD Program - New York

Oklahoma

  • IPS Research - Oklahoma City

Trial Details

FieldValue
Enrollment Target 295 participants
Start Date 2011-12
Est. Completion 2013-11
Phase Phase 2

Sponsor

Theravance Biopharma

38 total trials

What the Registry Record Tells You About NCT01458340

The ClinicalTrials.gov registry entry for NCT01458340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (59% higher). The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01458340 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Florida, Utah, Georgia.

Frequently Asked Questions

What is clinical trial NCT01458340 about?

NCT01458340 is a clinical study titled "A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.

What is the current status of trial NCT01458340?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2011-12. Estimated completion is 2013-11.

What conditions does trial NCT01458340 study?

This clinical trial studies the following conditions: ADHD, Attention Deficit/Hyperactivity Disorder.

What interventions are being tested in trial NCT01458340?

The interventions under investigation include: Placebo (DRUG), TD-9855 (DRUG).

Who is sponsoring clinical trial NCT01458340?

This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01458340 being conducted?

This trial has 17 study locations across Florida, Georgia, Kansas, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.